FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to immunology. Disclosed are an antibody or antigen-binding fragment thereof, specifically binding CD20. Also disclosed is a nucleic acid, an expression vector, a host cell and a method for producing a host cell. Also described is a method for producing the antibody, a pharmaceutical composition, a pharmaceutical combination, an inhibition method, a method of treating and using the antibody.
EFFECT: present invention can find further application in therapy of various diseases or disorders mediated by CD20, particularly oncological and autoimmune diseases.
36 cl, 17 tbl, 27 ex, 38 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
